BIOCRYST PHARMACEUTICALS, INC. Accounts Payable
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Accounts Payable of $11.46 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-05
- 2026-06-30: Accounts Payable, Current $11.46M.
- 2026-03-31: Accounts Payable, Current $10.96M.
- 2025-12-31: Accounts Payable, Current $15.83M.
- 2025-09-30: Accounts Payable, Current $5.57M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $11.46M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $10.96M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $15.83M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $5.57M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $8.59M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $10.05M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $11.64M 10-K · filed 2026-02-26 |
| 2024-09-30 | $13.48M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $7.79M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $11.91M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $20.89M 10-K · filed 2025-02-25 |
| 2023-09-30 | $10.57M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $13.89M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $6.25M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $14.36M 10-K · filed 2024-02-27 |
| 2022-09-30 | $8.62M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $12.02M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $13.88M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $27.81M 10-K · filed 2023-02-27 |
| 2021-09-30 | $19.69M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $10.09M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $13.53M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $18.71M 10-K · filed 2022-02-28 |
| 2020-09-30 | $11.62M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $9.35M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $10.06M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $13.99M 10-K · filed 2021-03-01 |
| 2019-09-30 | $10.08M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $8.30M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $6.93M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $7.77M 10-K · filed 2020-03-13 |
| 2018-09-30 | $7.91M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $4.12M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $3.59M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $6.34M 10-K · filed 2019-03-14 |
| 2017-09-30 | $4.60M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $1.84M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $5.43M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $4.27M 10-K · filed 2018-03-12 |
| 2016-09-30 | $2.76M 10-Q · filed 2016-11-08 |
| 2016-06-30 | $5.05M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $7.69M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $9.31M 10-K · filed 2017-02-27 |
| 2015-09-30 | $3.78M 10-Q · filed 2015-11-06 |
| 2015-06-30 | $3.82M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $5.31M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $2.85M 10-K · filed 2016-02-26 |
| 2014-09-30 | $2.27M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $2.36M 10-Q · filed 2014-08-08 |
| 2014-03-31 | $1.35M 10-Q · filed 2014-05-09 |
| 2013-12-31 | $4.17M 10-K · filed 2015-03-02 |
| 2013-09-30 | $1.24M 10-Q · filed 2013-11-08 |
| 2013-06-30 | $989.00K 10-Q · filed 2013-08-08 |
| 2013-03-31 | $1.07M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $3.97M 10-K · filed 2014-03-10 |
| 2012-09-30 | $2.29M 10-Q · filed 2012-11-08 |
| 2012-06-30 | $3.33M 10-Q · filed 2012-08-08 |
| 2012-03-31 | $2.06M 10-Q · filed 2012-05-08 |
| 2011-12-31 | $2.50M 10-K · filed 2013-03-11 |
| 2011-09-30 | $3.58M 10-Q · filed 2011-11-03 |
| 2011-06-30 | $5.01M 10-Q · filed 2011-08-04 |
| 2010-12-31 | $8.20M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |